泰林生物(300813.SZ):泰林新材料擬投建高性能過濾器及配套功能膜產業化項目
格隆匯4月27日丨泰林生物(300813.SZ)公佈,公司於2025年4月24日召開第四屆董事會第七次會議、第四屆監事會第七次會議,審議通過了《關於擬與杭州富春灣新城管理委員會簽訂高性能過濾器及配套功能膜產業化項目合同書的議案》,同意公司全資子公司浙江泰林新材料有限公司(簡稱“泰林新材料”)與杭州富春灣新城管理委員會簽署《高性能過濾器及配套功能膜產業化項目合同書》,在杭州富春灣新城投資建設“浙江泰林新材料有限公司高性能過濾器及配套功能膜產業化項目”(以下簡稱“本項目”)。本項目用地面積約30畝(最終用地面積以土地掛牌文件為準),項目總投資不低於3億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.